Date |
SE trades |
Over-the-counter |
||||||
---|---|---|---|---|---|---|---|---|
DVP | No. of securities units | Total nominal value | Turnover(EUR) | DVP | FOP | No. of securities units | Total nominal value | |
2024 September | 1 | 96,399 | ||||||
2023 December | 2 | 143,365 | ||||||
2023 November | 1 | 3,600 | ||||||
2023 August | 1 | 1 | 333,502 | |||||
2023 July | 1 | 307,000 | ||||||
2023 February | 1 | 5,000 | ||||||
2023 January | 1 | 70,845 | ||||||
2022 December | 1 | 59,175 | ||||||
2022 July | 1 | 433,802 | ||||||
2022 June | 1 | 10,000 | ||||||
2022 January | 1 | 75,928 | ||||||
2021 September | 1 | 1 | 149,104 | |||||
2021 July | 1 | 2 | 394,416 | |||||
2021 June | 2 | 3 | 1,457,816 | |||||
2021 February | 1 | 3 | 341,329 | |||||
2020 December | 1 | 2 | 405,146 | |||||
2020 November | 3 | 5 | 417,595 | |||||
2020 October | 2 | 3 | 525,679 | |||||
2020 August | 1 | 79,985 | ||||||
2020 June | 1 | 271,795 | ||||||
2020 May | 1 | 1 | 50,000 | |||||
2020 March | 2 | 2 | 329,428 | |||||
2020 February | 3 | 4 | 760,698 | |||||
2020 January | 1 | 1 | 265,400 | |||||
2019 December | 4 | 4 | 1,076,122 | |||||
2019 November | 1 | 3 | 264,571 | |||||
2019 October | 2 | 4 | 408,882 | |||||
2019 August | 1 | 56,050 | ||||||
2019 July | 6 | 5 | 2,327,471 | |||||
2019 June | 4 | 3 | 821,837 | |||||
2019 May | 10 | 2 | 2,309,484 | |||||
2019 April | 1 | 1 | 365,942 | |||||
2019 January | 3 | 1 | 763,360 | |||||
2018 October | 2 | 370,372 | ||||||
2018 September | 8 | 1 | 2,542,762 | |||||
2018 August | 6 | 1,667,504 |
Please note that settlement statistics part of the website only contains information about settled transactions starting from September 18, 2017 for Estonian, Latvian, and Lithuanian markets, and starting from August 24, 2020 - for Estonian, Latvian, Lithuanian and Icelandic markets.
The use of information contained on Nasdaq CSD website is governed by the Terms and Conditions. The use of statistical data for commercial purposes is the subject to additional fees. Please contact csd@nasdaq.com to receive further information.